Ultrasmall Superparamagnetic Nanoparticles Targeting E-selectin: Synthesis and Effects in Mice in Vitro and in Vivo
Overview
Affiliations
We developed a contrast agent for targeting E-selectin expression. We detected the agent using magnetic resonance imaging (MRI) in vivo in nude mice that had undergone nasopharyngeal carcinoma (NPC) metastasis. Sialyl Lewis X (sLe) was conjugated with ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles. Hydrodynamic size, polydispersity index, and ζ-potential of USPIO-polyethylene glycol (PEG) nanoparticles and USPIO-PEG-sLe nanoparticles were measured. Component changes in nanoparticles of USPIO, USPIO-PEG, and USPIO-PEG-sLe were analyzed by thermogravimetric analysis and Fourier-transform infrared spectroscopy. A model of NPC metastasis to inguinal lymph nodes in nude mice was used to investigate characteristics of the USPIO-PEG-sLe nanoparticles in vivo. We investigated the ability of the T2* value, change in T2* value (ΔT2* value), and enhancement rate (ER) to assess accumulation of USPIO-PEG-sLe nanoparticles quantitatively in mice of a metastasis group and control group. Four MRI scans were undertaken for each mouse. The first scan (t0) was done before administration of USPIO-PEG-sLe nanoparticles (0.1 mL) via the tail vein. The other scans were carried out at 0 (t1), 1 (t2), and 2 hours (t3) postinjection. The mean optical density was used to reflect E-selectin expression. sLe was labeled onto USPIO successfully. In vivo, there were significant interactions between the groups and time for T2* values after administration of USPIO-PEG-sLe nanoparticles. Six parameters (T2* at t2, ΔT2* at t1, ΔT2* at t2, ER at t1, ER at t2, and ER at t3) were correlated with the mean optical density. USPIO-PEG-sLe nanoparticles can be used to assess E-selectin expression quantitatively. Use of such molecular probes could enable detection of early metastasis of NPC, more accurate staging, and treatment monitoring.
Application of Nanoparticles in the Diagnosis and Treatment of Colorectal Cancer.
Song Q, Zheng Y, Zhong G, Wang S, He C, Li M Anticancer Agents Med Chem. 2024; 24(18):1305-1326.
PMID: 39129164 PMC: 11497148. DOI: 10.2174/0118715206323900240807110122.
Tang H, Zhou X, Liu L, Wang Z, Wang C, Luo N Mol Pharm. 2024; 21(6):2767-2780.
PMID: 38736196 PMC: 11152051. DOI: 10.1021/acs.molpharmaceut.3c01172.
Li T, Guo L, Li J, Mu X, Liu L, Song S Int J Nanomedicine. 2024; 19:1249-1272.
PMID: 38348177 PMC: 10859766. DOI: 10.2147/IJN.S445879.
Ji H, Hu C, Yang X, Liu Y, Ji G, Ge S Signal Transduct Target Ther. 2023; 8(1):367.
PMID: 37752146 PMC: 10522642. DOI: 10.1038/s41392-023-01576-4.
Yan Y, Liu Y, Li T, Liang Q, Thakur A, Zhang K J Nanobiotechnology. 2023; 21(1):337.
PMID: 37735449 PMC: 10512638. DOI: 10.1186/s12951-023-02100-0.